Hoffmann-La Roche
Entrectinib
Breast Cancer
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for Entrectinib in Breast Cancer are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT02568267: Phase 2 trial, sponsor Hoffmann-La Roche, drug Entrectinib. Primary completion date 2027-06-30 (estimated).”